SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders, announced today that the U.S. Drug Enforcement Administration (DEA) has designated XCOPRI® (cenobamate tablets) as a Schedule V medicine
March 10, 2020
· 9 min read